Immunotherapy developer Enlivex uses Bioblast shell to reverse merge its way onto Nasdaq
Capping a downward spiral since joining the Nasdaq biotech gold rush in 2014, Bioblast will serve as the shell for the reverse merger of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
